MedTrace Logo

Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer

NCT02605811 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 426

Last updated 2019-03-28

No results posted yet for this study

Summary

To investigate the response of temozolomide versus prophylactic cranial radiotherapy in preventing brain metastases in completed or partial remission limited small cell lung cancer patients.

Conditions

Interventions

DRUG

temozolomide

RADIATION

prophylaxis cranial radiotherapy

2

Sponsors & Collaborators

  • Guangzhou Medical University

    lead OTHER

Principal Investigators

  • Hailing Yang, MD · the first affiliated hospital of Guangzhou MC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2019-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02605811 on ClinicalTrials.gov